The global bleeding disorders testing market size was estimated to be USD 96.62 billion in 2023 and is expected to reach at USD 221.64 billion by 2034 with a CAGR of 7.84% during the forecast period 2024-2034. The expanding use of artificial intelligence & nanomaterials in the field of testing & diagnosis, rising prevalence of bleeding disorders, surge in technological advancements in the field of diagnosis of blood disorders, increasing awareness regarding the disorders among the population, growing potential of nano diagnostics is leading to a growing number of clinical studies focused on detecting bleeding disorders, rising investment in research & development activities by government organizations are some of the key factors boosting the market growth.
Rising investment in research & development activities by government organizations is predicted to boost the market growth during the forecast period. Research plays a crucial role in driving advancements and innovations in the development of test kits and instruments for diagnosing bleeding disorders like Hemophilia A, Hemophilia B, Von Willebrand Disease, and more. Thus, increased investment in research and development activities is leading to a greater number of launches of testing kits and instruments for bleeding disorders. For instance, in March 2023, The National Hemophilia Foundation has initiated a philanthropic fund called 'Pathway to Cures' with the aim of promoting the advancement of groundbreaking therapies and technologies for hereditary blood disorders.
By product, reagents & consumables was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the rising rate of testing is attributed to the development of healthcare infrastructure & improved healthcare access in emerging regions and surge in collaborations within market players. For instance, in March 2023, TruDiagnostic, a health data company, has partnered with NADMED, a Finnish firm specializing in nicotinamide adenine dinucleotide diagnostics, to create an innovative NAD+ blood diagnostic test capable of analyzing NAD+ and NADH levels from a small blood sample, catering to various clinical applications. Additionally, instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of bleeding disorders, increasing awareness regarding the bleeding disorders testing options, and increasing technological advancements to improve automation & portable analyzers.
By indication, hemophilia A was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the growing prevalence of bleeding disorders such as hemophilia A & B and increasing awareness regarding the availability of diagnostic options. Additionally, Von Willebrand disease is predicted to grow at fastest CAGR during the forecast period owing to the rising focus & efforts to develop guidelines for diagnosis & management of bleeding disorders such as Von Willebrand disease by government bodies & other healthcare organizations, surge in prevalence of Von Willebrand disease, increasing technological advancements, growing number of launches of hematology & hemostasis analyzers. For instance, in July 2022, HORIBA Medical is excited to introduce new additions to its Yumizen H500 & H550 hematology product line, comprising compact benchtop hematology analyzers that offer improved performance, new features, and enhanced benefits.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the growing awareness regarding bleeding disorders among the population, increasing prevalence of bleeding disorders, and rising rate of hospitalization, driven by the severity of these conditions, is creating a higher demand for testing instruments & reagents in hospitals & clinics. Additionally, diagnostic centers is predicted to grow at fastest CAGR during the forecast period owing to the surge in technological advancements, surge in healthcare infrastructure, rising launch of new products. For instance, in October 2022, The INNOVANCE VWF Ac assay, a completely automated test created for use with the Sysmex CS-2500 and CS-5100 hemostasis analyzers as well as the Siemens Healthineers BCS XP System, has been released by Siemens Healthineers.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of bleeding disorders, rising number of patient population, increasing launch of testing instruments & devices, and growing regulatory approvals. For instance, in June 2023, BioMarin has obtained approval from the U.S. FDA for its ROCTAVIAN gene therapy product, which is intended for the treatment of severe hemophilia A in adults. Roctavian is administered as a single intravenous infusion. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in awareness regarding bleeding disorders testing, and increasing donation programs for bleeding disorders testing. For instance, in April 2022, CSL Behring has made a generous donation of 500 million international units of coagulation factor replacement therapy to support the World Federation of Hemophilia's charitable aid program, aimed at assisting individuals dealing with bleeding disorders.
Rising investment in research & development activities by government organizations is predicted to boost the market growth during the forecast period. Research plays a crucial role in driving advancements and innovations in the development of test kits and instruments for diagnosing bleeding disorders like Hemophilia A, Hemophilia B, Von Willebrand Disease, and more. Thus, increased investment in research and development activities is leading to a greater number of launches of testing kits and instruments for bleeding disorders. For instance, in March 2023, The National Hemophilia Foundation has initiated a philanthropic fund called 'Pathway to Cures' with the aim of promoting the advancement of groundbreaking therapies and technologies for hereditary blood disorders.
By product, reagents & consumables was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the rising rate of testing is attributed to the development of healthcare infrastructure & improved healthcare access in emerging regions and surge in collaborations within market players. For instance, in March 2023, TruDiagnostic, a health data company, has partnered with NADMED, a Finnish firm specializing in nicotinamide adenine dinucleotide diagnostics, to create an innovative NAD+ blood diagnostic test capable of analyzing NAD+ and NADH levels from a small blood sample, catering to various clinical applications. Additionally, instruments is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of bleeding disorders, increasing awareness regarding the bleeding disorders testing options, and increasing technological advancements to improve automation & portable analyzers.
By indication, hemophilia A was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the growing prevalence of bleeding disorders such as hemophilia A & B and increasing awareness regarding the availability of diagnostic options. Additionally, Von Willebrand disease is predicted to grow at fastest CAGR during the forecast period owing to the rising focus & efforts to develop guidelines for diagnosis & management of bleeding disorders such as Von Willebrand disease by government bodies & other healthcare organizations, surge in prevalence of Von Willebrand disease, increasing technological advancements, growing number of launches of hematology & hemostasis analyzers. For instance, in July 2022, HORIBA Medical is excited to introduce new additions to its Yumizen H500 & H550 hematology product line, comprising compact benchtop hematology analyzers that offer improved performance, new features, and enhanced benefits.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global bleeding disorders testing market in 2023 owing to the growing awareness regarding bleeding disorders among the population, increasing prevalence of bleeding disorders, and rising rate of hospitalization, driven by the severity of these conditions, is creating a higher demand for testing instruments & reagents in hospitals & clinics. Additionally, diagnostic centers is predicted to grow at fastest CAGR during the forecast period owing to the surge in technological advancements, surge in healthcare infrastructure, rising launch of new products. For instance, in October 2022, The INNOVANCE VWF Ac assay, a completely automated test created for use with the Sysmex CS-2500 and CS-5100 hemostasis analyzers as well as the Siemens Healthineers BCS XP System, has been released by Siemens Healthineers.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of bleeding disorders, rising number of patient population, increasing launch of testing instruments & devices, and growing regulatory approvals. For instance, in June 2023, BioMarin has obtained approval from the U.S. FDA for its ROCTAVIAN gene therapy product, which is intended for the treatment of severe hemophilia A in adults. Roctavian is administered as a single intravenous infusion. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in awareness regarding bleeding disorders testing, and increasing donation programs for bleeding disorders testing. For instance, in April 2022, CSL Behring has made a generous donation of 500 million international units of coagulation factor replacement therapy to support the World Federation of Hemophilia's charitable aid program, aimed at assisting individuals dealing with bleeding disorders.
Segmentation: Bleeding Disorders Testing Market Report 2023 - 2034
Bleeding Disorders Testing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments
- Reagents & Consumables
Bleeding Disorders Testing Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Von Willebrand Disease
- Hemophilia A & B
- Idiopathic Thrombocytopenic Purpura
- Others
Bleeding Disorders Testing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals & Clinics
- Diagnostic Centers
- Others
Bleeding Disorders Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Bleeding Disorders Testing Market: Product Estimates & Trend Analysis
8. Bleeding Disorders Testing Market: Indication Estimates & Trend Analysis
9. Bleeding Disorders Testing Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Bleeding Disorders Testing Market
12. Europe Global Bleeding Disorders Testing Market
13. Asia Pacific Global Bleeding Disorders Testing Market
14. Latin America Global Bleeding Disorders Testing Market
15. MEA Global Bleeding Disorders Testing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Siemens Healthcare GmbH
- Medexus Pharma Inc.
- HORIBA Ltd.
- CSL Limited
- Sysmex Corporation
- Grifols
- S.A.
- Abbott
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc
- Novo Nordisk A/S
- Atlas Medical GmbH
- Sanofi
- HYPHEN BioMed
- F. Hoffmann-La Roche Ltd.
- Precision Biologics
- Bayer AG
- Pfizer Inc.
- Octapharma AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 96.62 Billion |
| Forecasted Market Value ( USD | $ 221.64 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 19 |
